By Wilfredo Mateo, Director, Manufacturing Sciences & Technology, Emergent BioSolutions
Regardless of where a drug candidate is in the development pipeline, performing a technology transfer (tech transfer) presents unique challenges for the partners involved. Overcoming these challenges is critical to ensuring the ultimate success of the product when working with a Contract Development and Manufacturing Organization (CDMO). There are a myriad of ways in which a tech transfer can fail to meet its potential – unsatisfactory yields, unforeseen materials shortages, unoptimized batch sizes that can impact the quality and timelines of the transferred product.
This is why engaging a partner with the expertise and protocols needed to conduct a comprehensive tech transfer is key to mitigating this risk. By vetting CDMOs for their regulatory track records, historical time-to-market, facilities, capabilities, and internal procedures, both companies can establish a partnership best suited to their goals.
At Emergent CDMO, customers are afforded a range of options for exploring, expanding, or expediting their manufacturing processes. With a long-standing history of commercial manufacturing success, Emergent possesses the knowledge and talent to analyze risk, perform scale-up, and optimize production, creating efficiencies and controlling costs.